NanoViricides, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNVC research report →
Price Chart
About the company
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses.
- CEO
- Anil R. Diwan
- IPO
- 2005
- Employees
- 7
- HQ
- Shelton, CT, US
Get TickerSpark's AI analysis on NNVC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.56M
- P/E
- -3.40
- Fwd P/E
- 2.80
- PEG
- -0.07
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 362109.25
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.00%
- ROIC
- -0.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-525,286+0.0%
- Op Income
- $-8,306,361
- Net Income
- $-8,218,508+13.2%
- EPS
- $-0.41+34.9%
- OCF Growth
- -90768933.7%
- FCF Growth
- -91150994.3%
- 52W High
- $2.23
- 52W Low
- $0.85
- 50D MA
- $1.33
- 200D MA
- $1.27
- Beta
- 1.79
- RSI (14)
- 53
- Avg Volume
- 449.24K
No earnings-call transcripts are available for NNVC yet.
- Free Float
- 83.0%
- Shares Outstanding
- 25.40M
- Float Shares
- 21.08M
of shares held by institutions
49 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NNVC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kelly LoefflerSenate · GA | Sell | Apr 7, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 919.31K | ▲ 407.84K |
| Vanguard Group Inc | 605.58K | 0 |
| Geode Capital Management, LLC | 216.02K | ▼ 9.36K |
| Connective Capital Management, LLC | 185.22K | ▲ 185.22K |
| Blackrock, Inc. | 158.75K | ▲ 1 |
| Vanguard Fiduciary Trust Co | 131.92K | ▲ 41.86K |
| Renaissance Technologies LLC | 128.60K | ▼ 6.30K |
| Miller Financial Services LLC | 112.00K | ▲ 7.00K |
| Ubs Group AG | 99.33K | ▼ 114.03K |
| Creative Planning | 86.76K | ▲ 86.76K |
| Susquehanna International Group, Llp | 60.62K | ▼ 38.41K |
| State Street Corp | 54.21K | 0 |
Held by 23 ETFs
Biggest fund positions in NNVC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 21, 17 | BONIUK MILTON | other | 0 |
| Feb 21, 17 | Stephenson Fournier, PLLC | other | 0 |
| Aug 8, 22 | Diwan Anil | other | 94,471 |
| Feb 7, 20 | Jawadakar Makarand | other | 0 |
| Jun 2, 19 | Day Mark D. | other | 0 |
| May 21, 18 | BONIUK MILTON | other | 5,500,000 |
| Feb 21, 17 | BONIUK MILTON | other | 1,746,288 |
| Jul 11, 17 | BONIUK MILTON | other | 120,744 |
| May 4, 17 | BONIUK MILTON | other | 149,478 |
| Feb 21, 17 | BONIUK MILTON | other | 153,611 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NNVC coverage
Recent articles, reports, and earnings notes.
No research on NNVC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNVC report →NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
accessnewswire.com · Oct 6
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
accessnewswire.com · Oct 5
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
accessnewswire.com · Sep 29
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
accessnewswire.com · Sep 28
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
accessnewswire.com · Sep 23
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
accessnewswire.com · Sep 15
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
accessnewswire.com · Sep 8
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
accessnewswire.com · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.